• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

25.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 466
Open 25.23
Bid (Size) 24.50 (100)
Ask (Size) 25.23 (900)
Prev. Close 25.23
Today's Range 25.23 - 25.23
52wk Range 9.030 - 28.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
March 02, 2026
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗
March 02, 2026
Via Chartmill

Performance

YTD
-5.2%
-5.2%
1 Month
+8.9%
+8.9%
3 Month
-3.8%
-3.8%
6 Month
+78.4%
+78.4%
1 Year
+97.9%
+97.9%

More News

Read More
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 02, 2026
From Zymeworks Inc.
Via GlobeNewswire
ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗
January 01, 2026
Via Chartmill
News headline image
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
February 12, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
January 27, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
January 12, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Outlines Strategic Priorities and Outlook for 2026
January 11, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
January 06, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
December 02, 2025
Via Chartmill
News headline image
Zymeworks Announces Participation in Upcoming Conferences
December 02, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
November 24, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗
November 24, 2025
Via Stocktwits
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
November 18, 2025
Via Benzinga
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
Via FinancialNewsMedia
News headline image
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
November 18, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
November 18, 2025
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
November 17, 2025
Via Chartmill
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
November 17, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
November 17, 2025
Via Benzinga
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
November 17, 2025
Via Benzinga

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 25.23
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 03/04/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap